These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27253864)

  • 1. The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.
    Liu X; Low SK; Boddy AV
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):851-63. PubMed ID: 27253864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.
    Borrie AE; Kim RB
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):149-156. PubMed ID: 27635473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.
    Rumiato E; Brunello A; Ahcene-Djaballah S; Borgato L; Gusella M; Menon D; Pasini F; Amadori A; Saggioro D; Zagonel V
    Pharmacogenomics J; 2016 Nov; 16(6):525-529. PubMed ID: 26503812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of aromatase inhibitor therapy in breast cancer.
    Lintermans A; Neven P
    Expert Opin Drug Saf; 2015 Aug; 14(8):1201-11. PubMed ID: 26059833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of third-generation aromatase inhibitors.
    Turkistani A; Marsh S
    Expert Opin Pharmacother; 2012 Jun; 13(9):1299-307. PubMed ID: 22594760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of aromatase inhibitors.
    Hadfield KD; Newman WG
    Pharmacogenomics; 2012 Apr; 13(6):699-707. PubMed ID: 22515612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy with aromatase inhibitors in postmenopausal, estrogen receptor- positive breast cancer patients: upfront or sequential?
    Dediu M; Median D; Alexandru A; Vremes G; Gal C; Gongu M
    J BUON; 2009; 14(3):375-9. PubMed ID: 19810126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When should we give aromatase inhibitors for insomnia; early in the day or after dinner?
    Ates O; Sunar V; Sever AR; Altundag K
    J BUON; 2016; 21(2):521. PubMed ID: 27273969
    [No Abstract]   [Full Text] [Related]  

  • 11. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
    Ingle JN
    Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.
    Kadakia KC; Snyder CF; Kidwell KM; Seewald NJ; Flockhart DA; Skaar TC; Desta Z; Rae JM; Otte JL; Carpenter JS; Storniolo AM; Hayes DF; Stearns V; Henry NL
    Oncologist; 2016 May; 21(5):539-46. PubMed ID: 27009936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aromatase inhibitors and arthralgia].
    Nagykálnai T; Landherr L; Mészáros E
    Magy Onkol; 2011 Mar; 55(1):32-9. PubMed ID: 21617789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular effects of aromatase inhibitors: data from clinical trials.
    Howell A; Cuzick J
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):143-9. PubMed ID: 15936188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug safety evaluation of exemestane.
    Lintermans A; Neven P; Paridaens R
    Expert Opin Drug Saf; 2011 May; 10(3):473-87. PubMed ID: 21428848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
    Ryan PD; Goss PE
    Oncologist; 2006; 11(7):718-31. PubMed ID: 16880231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase inhibitors and musculoskeletal symptoms.
    Khanduri S; Dodwell DJ
    Breast; 2008 Feb; 17(1):76-9. PubMed ID: 17822901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.